Evidence map›Paper›PMID 35372378›Full record

ArticleFrontiers in medicine2022

Machine Learning Improves Upon Clinicians' Prediction of End Stage Kidney Disease.

Aaron Chuah, Giles Walters, Daniel Christiadi, Krishna Karpe, Alice Kennard, Richard Singer, Girish Talaulikar, Wenbo Ge, Hanna Suominen, T Daniel Andrews and 1 more

Abstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Aaron ChuahDepartment of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University (ANU), Canberra, ACT, Australia.
Giles WaltersDepartment of Renal Medicine, The Canberra Hospital, Garran, ACT, Australia.
Daniel ChristiadiDepartment of Renal Medicine, The Canberra Hospital, Garran, ACT, Australia.
Krishna KarpeDepartment of Renal Medicine, The Canberra Hospital, Garran, ACT, Australia.
Alice KennardDepartment of Renal Medicine, The Canberra Hospital, Garran, ACT, Australia.
Richard SingerDepartment of Renal Medicine, The Canberra Hospital, Garran, ACT, Australia.
Girish TalaulikarDepartment of Renal Medicine, The Canberra Hospital, Garran, ACT, Australia.
Wenbo GeSchool of Computing, Australian National University, ACT, Australia.
Hanna SuominenSchool of Computing, Australian National University, ACT, Australia.
T Daniel AndrewsDepartment of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University (ANU), Canberra, ACT, Australia.
Simon JiangDepartment of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University (ANU), Canberra, ACT, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Chronic kidney disease progression to ESKD is associated with a marked increase in mortality and morbidity. Its progression is highly variable and difficult to predict. Methods: This is an observational, retrospective, single-centre study. The cohort was patients attending hospital and nephrology clinic at The Canberra Hospital from September 1996 to March 2018. Demographic data, vital signs, kidney function test, proteinuria, and serum glucose were extracted. The model was trained on the featurised time series data with XGBoost. Its performance was compared against six nephrologists and the Kidney Failure Risk Equation (KFRE). Results: A total of 12,371 patients were included, with 2,388 were found to have an adequate density (three eGFR data points in the first 2 years) for subsequent analysis. Patients were divided into 80%/20% ratio for training and testing datasets.ML model had superior performance than nephrologist in predicting ESKD within 2 years with 93.9% accuracy, 60% sensitivity, 97.7% specificity, 75% positive predictive value. The ML model was superior in all performance metrics to the KFRE 4- and 8-variable models.eGFR and glucose were found to be highly contributing to the ESKD prediction performance. Conclusions: The computational predictions had higher accuracy, specificity and positive predictive value, which indicates the potential integration into clinical workflows for decision support.

Indexed as

chronic kidney diseaseend stage kidney disease (ESKD)machine learning (ML)prediction modelXGBoost (Extreme Gradient Boosting)

Identifiers

PMID35372378
PMCPMC8965763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.